Alzheimer’s disease (AD), associated with abnormal accumulation of amyloid-β (Aβ), is the most common cause of dementia among older people. A few studies have identified substantial AD biomarkers in blood but their results were inconsistent. Here we screened gene expression alterations on Aβ-GFP SH-SY5Y neuronal model for AD, and evaluated the findings on peripheral leukocytes from 78 patients with AD and 56 healthy controls. The therapeutic responses of identified biomarker candidates were further examined in Aβ-GFP SH-SY5Y neuronal and APP/PS1/Tau triple transgenic (3×Tg-AD) mouse models. Downregulation of apolipoprotein E (APOE) and tropomyosin receptor kinase A (TRKA) were detected in Aβ-GFP SH-SY5Y cells and validated by peripheral leukocytes from AD patients. Treatment with an in-house indole compound NC009-1 upregulated the expression of APOE and TRKA accompanied with improvement of neurite outgrowth in Aβ-GFP SH-SY5Y cells. NC009-1 further rescued the downregulated APOE and TRKA and reduced Aβ and tau levels in hippocampus and cortex, and ameliorated cognitive deficits in streptozocin-induced hyperglycemic 3×Tg-AD mice. These results suggest the role of APOE and TRKA as potential peripheral biomarkers in AD, and offer a new drug development target of AD treatment. Further studies of a large series of AD patients will be warranted to verify the findings and confirm the correlation between these markers and therapeutic efficacy.
QuerfurthHW, LaFerlaFM (2010) Alzheimer’s disease. N Engl J Med362, 329–344.
2.
RoherAE, LowensonJD, ClarkeS, WoodsAS, CotterRJ, GowingE, BallMJ (1993) β-Amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: Implications for the pathology of Alzheimer disease. Proc Natl Acad Sci U S A90, 10836–10840.
AlbertMS, DeKoskyST, DicksonD, DuboisB, FeldmanHH, FoxNC, GamstA, HoltzmanDM, JagustWJ, PetersenRC, SnyderPJ, CarrilloMC, ThiesB, PhelpsCH (2011) The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 270–279.
5.
LangaKM, LevineDA (2014) The diagnosis and management of mild cognitive impairment: A clinical review. JAMA312, 2551–2561.
6.
RitchieC, SmailagicN, Noel-StorrAH, UkoumunneO, LaddsEC, MartinS (2017) CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev3, CD010803.
7.
EwersM, SperlingRA, KlunkWE, WeinerMW, HampelH (2011) Neuroimaging markers for the prediction and early diagnosis of Alzheimer’s disease dementia. Neurosci34, 430–442.
8.
HuijbersW, MorminoEC, SchultzAP, WigmanS, WardAM, LarvieM, AmariglioRE, MarshallGA, RentzDM, JohnsonKA, SperlingRA (2015) Amyloid-β deposition in mild cognitive impairment is associated with increased hippocampal activity, atrophy and clinical progression. Brain138, 1023–1035.
9.
MattssonN, ZetterbergH, HanssonO, AndreasenN, ParnettiL, JonssonM, HerukkaSK, van der FlierWM, BlankensteinMA, EwersM, RichK, KaiserE, VerbeekM, TsolakiM, MulugetaE, RosénE, AarslandD, VisserPJ, SchröderJ, MarcussonJ, de LeonM, HampelH, ScheltensP, PirttiläT, WallinA, JönhagenME, MinthonL, WinbladB, BlennowK (2009) CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA302, 385–393.
10.
PetersenRC, AisenP, BoeveB, GedaYE, IvnikRJ, KnopmanDS, MielkeM, PankratzVS, RobertsR, RoccaWA, WeigandS, WeinerM, WisteH, JackCRJr (2013) Mild cognitive impairment due to Alzheimer disease in the community. Ann Neurol74, 199–208.
11.
Cedazo-MinguezA, WinbladB (2010) Biomarkers for Alzheimer’s disease and other forms of dementia: Clinical needs, limitations and future aspects. Exp Gerontol45, 5–14.
12.
ZetterbergH, BlennowK, HanseE (2010) Amyloid β and APP as biomarkers for Alzheimer’s disease. Exp Gerontol45, 23–29.
13.
ChenA, OakleyAE, MonteiroM, TuomelaK, AllanLM, Mukaetova-LadinskaEB, O’BrienJT, KalariaRN (2016) Multiplex analyte assays to characterize different dementias: Brain inflammatory cytokines in poststroke and other dementias. Neurobiol Aging38, 56–67.
14.
ChoiC, JeongJH, JangJS, ChoiK, LeeJ, KwonJ, ChoiKG, LeeJS, KangSW (2008) Multiplex analysis of cytokines in the serum and cerebrospinal fluid of patients with Alzheimer’s disease by color-coded bead technology. J Clin Neurol4, 84–88.
15.
DelabyC, GabelleA, BlumD, Schraen-MaschkeS, MoulinierA, BoulanghienJ, SeveracD, BueeL, RemeT, LehmannS (2015) Central nervous system and peripheral inflammatory processes in Alzheimer’s disease: Biomarker profiling approach. Front Neurol6, 181.
16.
HochstrasserT, MarksteinerJ, DefrancescoM, DeisenhammerEA, KemmlerG, HumpelC (2011) Two blood monocytic biomarkers (CCL15 and p21) combined with the Mini-Mental State Examination discriminate Alzheimer’s disease patients from healthy subjects. Dement Geriatr Cogn Dis Extra1, 297–309.
17.
LaskeC, SchmohlM, LeyheT, StranskyE, MaetzlerW, BergD, FallgatterAJ, JoosT, DietzschJ (2013) Immune profiling in blood identifies sTNF-R1 performing comparably well as biomarker panels for classification of Alzheimer’s disease patients. J Alzheimers Dis34, 367–375.
18.
RameshC, KavalaV, RajuBR, KuoCW, YaoCF (2009) Novel synthesis of indolylquinoline derivatives via the C-alkylation of Baylis–Hillman adducts. Tetrahedron Lett50, 4037–4041.
19.
ChangKH, ChiuYJ, ChenSL, HuangCH, LinCH, LinTH, LeeCM, RameshC, WuCH, HuangCC, FungHC, ChenYC, LinJY, YaoCF, HuangHJ, Lee-ChenGJ, LeeMC, Hsieh-LiHM (2016) The potential of synthetic indolylquinoline derivatives for Aβ aggregation reduction by chemical chaperone activity. Neuropharmacology101, 309–319.
20.
ChangKH, LinCH, ChenHC, HuangHY, ChenSL, LinTH, RameshC, HuangCC, FungHC, WuYR, HuangHJ, Lee-ChenGJ, Hsieh-LiHM, YaoCF (2017) The potential of indole/indolylquinoline compounds in tau misfolding reduction by enhancement of HSPB1. CNS Neurosci Ther23, 45–56.
21.
ChenCM, ChenWL, HungCT, LinTH, ChaoCY, LinCH, WuYR, ChangKH, YaoCF, Lee-ChenGJ, SuMT, Hsieh-LiHM (2018) The indole compound NC009-1 inhibits aggregation and promotes neurite outgrowth through enhancement of HSPB1 in SCA17 cells and ameliorates the behavioral deficits in SCA17 mice. Neurotoxicology67, 259–269.
22.
McKhannGM, KnopmanDS, ChertkowH, HymanBT, JackCR, KawasCH, KlunkWE, KoroshetzWJ, ManlyJJ, MayeuxR, MohsRC, MorrisJC, RossorMN, ScheltensP, CarrilloMC, ThiesB, WeintraubS, PhelpsCH (2011) The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 263–269.
23.
FolsteinMF, FolsteinSE, McHughPR (1975) “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res12, 189–198.
24.
MorrisJC (1993) The Clinical Dementia Rating (CDR): Current version and scoring rules. Neurology43, 2412–2414.
25.
OddoS, CaccamoA, ShepherdJD, MurphyMP, GoldeTE, KayedR, MetherateR, MattsonMP, AkbariY, LaFerlaFM (2003) Triple-transgenic model of Alzheimer’s disease with plaques and tangles: Intracellular Aβ and synaptic dysfunction. Neuron39, 409–421.
ShuJ, FuH, QiuG, KayeP, IlyasM (2013) Segmenting overlapping cell nuclei in digital histopathology images. Conf Proc IEEE Eng Med Biol Soc2013, 5445–5448.
28.
MiseA, YoshinoY, YamazakiK, OzakiY, SaoT, YoshidaT, MoriT, MoriY, OchiS, IgaJI, UenoSI (2017) TOMM40 and APOE gene expression and cognitive decline in Japanese Alzheimer’s disease subjects. J Alzheimers Dis60, 1107–1117.
29.
BaiZ, StamovaB, XuH, AnderBP, WangJ, JicklingGC, ZhanX, LiuD, HanG, JinLW, DeCarliC, LeiH, SharpFR (2014) Distinctive RNA expression profiles in blood associated with Alzheimer’s disease after accounting for white matter hyperintensities. Alzheimer Dis Assoc Disord28, 226–233.
30.
ChenKD, ChangPT, PingYH, LeeHC, YehCW, WangPN (2011) Gene expression profiling of peripheral blood leukocytes identifies and validates ABCB1 as a novel biomarker for Alzheimer’s disease. Neurobiol Dis43, 698–705.
31.
QiuZ, HymanBT, RebeckGW (2004) Apolipoprotein E receptors mediate neurite outgrowth through activation of p44/42 mitogen-activated protein kinase in primary neurons. J Biol Chem279, 34948–34956.
32.
HoeHS, HarrisDC, RebeckGW (2005) Multiple pathways of apolipoprotein E signaling in primary neurons. J Neurochem93, 145–155.
33.
HoweCL, VallettaJS, RusnakAS, MobleyWC (2001) NGF signaling from clathrin-coated vesicles: Evidence that signaling endosomes serve as a platform for the Ras-MAPK pathway. Neuron32, 801–814.
34.
DelcroixJD, VallettaJS, WuC, HuntSJ, KowalAS, MobleyWC (2003) NGF signaling in sensory neurons: Evidence that early endosomes carry NGF retrograde signals. Neuron39, 69–84.
35.
BillingsLM, OddoS, GreenKN, McGaughJL, LaFerlaFM (2005) Intraneuronal Aβ causes the onset of early Alzheimer’s disease related cognitive deficits in transgenic mice. Neuron45, 675–688.
36.
MosconiL (2005) Brain glucose metabolism in the early and specific diagnosis of Alzheimer’s disease. FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging32, 486–510.
37.
WolfHK, BusleiR, Schmidt-KastnerR, Schmidt-KastnerPK, PietschT, WiestlerOD, BlümckeI (1996) NeuN: A useful neuronal marker for diagnostic histopathology. J Histochem Cytochem44, 1167–1171.
CramerPE, CirritoJR, WessonDW, LeeCY, KarloJC, ZinnAE, CasaliBT, RestivoJL, GoebelWD, JamesMJ, BrundenKR, WilsonDA, LandrethGE (2012) ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models. Science335, 1503–1506.
42.
XuQ, BernardoA, WalkerD, KanegawaT, MahleyRW, HuangY (2006) Profile and regulation of apolipoprotein E (ApoE) expression in the CNS in mice with targeting of green fluorescent protein gene to the ApoE locus. J Neurosci26, 4985–4994.
43.
ZhaoL, LinS, BalesKR, GelfanovaV, KogerD, DelongC, HaleJ, LiuF, HunterJM, PaulSM (2009) Macrophage-mediated degradation of β-amyloid via an apolipoprotein E isoform-dependent mechanism. J Neurosci29, 3603–3612.
44.
DonkinJJ, StukasS, Hirsch-ReinshagenV, NamjoshiD, WilkinsonA, MayS, ChanJ, FanJ, CollinsJ, WellingtonCL (2010) ATP-binding cassette transporter A1 mediates the beneficial effects of the liver X receptor agonist GW3965 on object recognition memory and amyloid burden in amyloid precursor protein/presenilin 1 mice. J Biol Chem285, 34144–34154.
45.
LambertJC, MannD, RichardF, TianJ, ShiJ, ThakerU, MerrotS, HarrisJ, FrigardB, IwatsuboT, LendonC, AmouyelP (2005) Is there a relation between APOE expression and brain amyloid load in Alzheimer’s disease?J Neurol Neurosurg Psychiatry76, 928–933.
46.
WangC, YuJT, WangHF, JiangT, TanCC, MengXF, SoaresHD, TanL (2014) Meta-analysis of peripheral blood apolipoprotein E levels in Alzheimer’s disease. PLoS One9, e89041.
47.
AkramA, SchmeidlerJ, KatselP, HofPR, HaroutunianV (2012) Association of ApoE and LRP mRNA levels with dementia and AD neuropathology. Neurobiol Aging33, 628.e1–628.e14.
48.
ChaoMV (2003) Neurotrophins and their receptors: A convergence point for many signalling pathways. Nat Rev Neurosci4, 299–309.
49.
CanuN, AmadoroG, TriacaV, LatinaV, SposatoV, CorsettiV, SeveriniC, CiottiMT, CalissanoP (2017) The intersection of NGF/TrkA signaling and amyloid precursor protein processing in Alzheimer’s disease neuropathology. Int J Mol Sci18, 1319.
50.
CountsSE, NadeemM, WuuJ, GinsbergSD, SaragoviHU, MufsonEJ (2004) Reduction of cortical TrkA but not p75(NTR) protein in early-stage Alzheimer’s disease. Ann Neurol56, 520–531.
51.
CrispoltoniL, StabileAM, PistilliA, VenturelliM, CerulliG, FonteC, SmaniaN, SchenaF, RendeM (2017) Changes in plasma β-NGF and its receptors expression on peripheral blood monocytes during Alzheimer’s disease progression. J Alzheimers Dis55, 1005–1017.
52.
CohenT, Frydman-MaromA, RechterM, GazitE (2006) Inhibition of amyloid fibril formation and cytotoxicity by hydroxyindole derivatives. Biochemistry45, 4727–4735.
53.
LieuVH, WuJW, WangSS, WuCH (2007) Inhibition of amyloid fibrillization of hen egg-white lysozymes by rifampicin and p-benzoquinone. Biotechnol Prog23, 698–706.
54.
PoratY, AbramowitzA, GazitE (2006) Inhibition of amyloid fibril formation by polyphenols: Structural similarity and aromatic interactions as a common inhibition mechanism. Chem Biol Drug Des67, 27–37.
55.
PickhardtM, GazovaZ, von BergenM, KhlistunovaI, WangY, HascherA, MandelkowEM, BiernatJ, MandelkowE (2005) Anthraquinones inhibit tau aggregation and dissolve Alzheimer’s paired helical filaments in vitro and in cells. J Biol Chem280, 3628–3635.
56.
ChyanYJ, PoeggelerB, OmarRA, ChainDG, FrangioneB, GhisoJ, PappollaMA (1999) Potent neuroprotective properties against the Alzheimer β-amyloid by an endogenous melatonin-related indole structure, indole-3-propionic acid. J Biol Chem274, 21937–21942.
57.
Hornedo-OrtegaR, Da CostaG, CerezoAB, TroncosoAM, RichardT, Garcia-ParrillaMC (2018) In vitro effects of serotonin, melatonin, and other related indole compounds on amyloid-β kinetics and neuroprotection. Mol Nutr Food Res62, 1700383.
58.
OhKJ, PerezSE, LagalwarS, VanaL, BinderL, MufsonEJ (2010) Staging of Alzheimer’s pathology in triple transgenic mice: A light and electron microscopic analysis. Int J Alzheimers Dis2010, 780102.
59.
YanXX, CaiY, SheltonJ, DengSH, LuoXG, OddoS, LaferlaFM, CaiH, RoseGM, PatryloPR (2012) Chronic temporal lobe epilepsy is associated with enhanced Alzheimer-like neuropathology in 3×Tg-AD mice. PLoS One7, e48782.
60.
StokinGB, LilloC, FalzoneTL, BruschRG, RockensteinE, MountSL, RamanR, DaviesP, MasliahE, WilliamsDS, GoldsteinLS (2005) Axonopathy and transport deficits early in the pathogenesis of Alzheimer’s disease. Science307, 1282–1288.
61.
RipoliC, CoccoS, Li PumaDD, PiacentiniR, MastrodonatoA, ScalaF, PuzzoD, D’AscenzoM, GrassiC (2014) Intracellular accumulation of amyloid-β (Aβ) protein plays a major role in Aβ-induced alterations of glutamatergic synaptic transmission and plasticity. J Neurosci34, 12893–12903.
62.
TalwarP, GuptaR, KushwahaS, AgarwalR, SasoL, KukretiS, KukretiR (2018) Viral induced oxidative and inflammatory response in Alzheimer’s disease pathogenesis with identification of potential drug candidates: A systematic review using systems biology approach. Curr Neuropharmacol, doi: 10.2174/1570159X16666180419124508
WangX, YuS, HuJP, WangCY, WangY, LiuHX, LiuYL (2014) Streptozotocin-induced diabetes increases amyloid plaque deposition in AD transgenic mice through modulating AGEs/RAGE/NF-kappaB pathway. Int J Neurosci124, 601–608.
65.
BharadwajP, WijesekaraN, LiyanapathiranaM, NewsholmeP, IttnerL, FraserP, VerdileG (2017) The link between type 2 diabetes and neurodegeneration: Roles for amyloid-β, amylin, and tau proteins. J Alzheimers Dis59, 421–432.
66.
MullinsRJ, DiehlTC, ChiaCW, KapogiannisD (2017) Insulin resistance as a link between amyloid-beta and tau pathologies in Alzheimer’s disease. Front Aging Neurosci9, 118.
67.
QuZS, LiL, SunXJ, ZhaoYW, ZhangJ, GengZ, FuJL, RenQG (2014) Glycogen synthase kinase-3 regulates production of amyloid-β peptides and tau phosphorylation in diabetic rat brain. ScientificWorldJournal2014, 878123.
68.
ZhangY, HuangNQ, YanF, JinH, ZhouSY, ShiJS, JinF (2018) Diabetes mellitus and Alzheimer’s disease: GSK-3β as a potential link. Behav Brain Res339, 57–65.
